Memantina Doc (Memantine Hydrochloride)

Memantine works by binding to the NMDA‑type glutamate receptor at a site separate from the glutamate binding region. This non‑competitive antagonism limits excessive calcium entry into neurons during prolonged glutamate stimulation, thereby reducing excitotoxic damage that contributes to the progression of Alzheimer’s disease.

The dosage of Memantina Doc is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. No fixed regimen is provided here; the prescriber will establish the appropriate dose and titration schedule.

Safety data for memantine in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks with their healthcare provider.

To request Memantina Doc, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements), and necessary import documentation.

The primary alternative class for Alzheimer’s disease is acetylcholinesterase inhibitors such as donepezil. While those agents increase acetylcholine levels to improve cognition, memantine targets glutamatergic excitotoxicity via NMDA‑receptor antagonism. Clinically, memantine is often added to or used instead of an acetylcholinesterase inhibitor in moderate to severe disease, offering a different mechanism of action.

Memantina Doc should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct light, and ensure the packaging remains sealed until use. No refrigeration is required for this oral formulation.

Memantina Doc is administered orally, usually as a tablet taken with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether the dose should be taken in a single daily administration or divided throughout the day.

Serious adverse events include seizures, severe allergic reactions (such as rash, swelling, or breathing difficulty), hallucinations, and cardiac arrhythmias. If any of these occur, immediate medical attention is required. Patients should also be monitored for worsening confusion or behavioral changes.

Memantina Doc should be avoided in individuals with known hypersensitivity to memantine or any excipients in the formulation. It is also contraindicated in patients with severe renal impairment where dose adjustment is not feasible, and in those with uncontrolled epilepsy due to the potential to lower seizure threshold.